US pricing pressure on Dapsone
New competitors for Dapsone (Torrent's leading US product) continue to impact revenues. Management expects 8 approvals in FY25 but competitive intensity remains elevated.
TORNTPHARM / Q4-FY24 / risks
Keep the risk register visible.
Torrent Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Brazil price growth moderation
Price growth in Brazil is ~4% (vs ~10% market growth). While volume and new products compensate, any further pricing pressure could impact growth trajectory toward BRL 1 billion target.
Red Sea impact on freight costs
Freight expenses increased by ~INR 10 crore in Q4 due to Red Sea disruptions. Extended transit times and cost pressures could persist and compress margins if not managed.
Trade generics impact on IPM volumes
Analyst raised concern about trade generics impacting chronic volumes in IPM. Management acknowledged difficulty gaining traction in chronic space but noted competitive intensity increasing across segments.